The past few decades have seen an exponential rise in our appreciation of how cancer cells differ from normal cells. Increasing numbers of TARGETED PRECISION MEDICINES have been developed which have greatly added to the options available for cancer treatments. These use as targets, unique molecular properties of cancer.
IMMUNOTHERAPY meanwhile, looks to exploit mechanisms by which the body's immune system can attack and eliminate cancer cells.
The ARC Paradigm® is focused on something quite different. We are interested in features of NORMALCY that are lost in cancer that might be regained. The postulation is that these facets of normal-ness may affect the operational 'milieu' of a cancer and the environment in which immunotherapy, and an individual's immunology more widely, can work.
Through the CCRT's RSII™ Initiative, we first look to create new insights that can yield new knowledge, from which new avenues for clinical options might hypothetically eventually be generated. But not until we know what the 'right questions' would even be!
At this very initial stage, via the CCRT's RSII™ Initiative, we are undertaking a process of divergent thinking about facets of health that might be supported, tested and mapped in an individual, in the context of cancer. And developing ever more questions about what these might, perhaps, mean to the individual's ability to fight cancer, survive and, may be, live with cancer. Which may be important given that 1 in 2 of us can expect to develop cancer during our lifetimes.
Is there an optimal way to 'be successful' with cancer, through health?
Because this Initiative is about creating new Intelligence, it follows our own RSII™ Algorithms and Protocols, in which we undertake an elaborate and extensive process of reconnaissance, surveillance and interrogation.